In short
Lufepirsen is being studied in clinical trials for eye disease, especially persistent corneal epithelial defects. These trials look at safety and how well the treatment helps the cornea heal, mainly in adults with this condition.
Key points
- Lufepirsen is being studied in a Phase 2 clinical trial for persistent corneal epithelial defects, which are areas on the cornea that do not heal well. The study is testing NEXAGON, an ophthalmic gel containing Lufepirsen, against a vehicle gel without the active ingredient. Researchers are looking at both safety and whether the cornea heals and stays healed for at least 28 days. The trial is interventional and plans to enroll 120 subjects. The main outcome is the proportion of subjects with lasting corneal re-epithelialization, measured by review of corneal fluorescein staining images.
Trial overview
The available trial for Lufepirsen is NCT05966493, titled a clinical trial to evaluate the safety and the efficacy of NEXAGON in subjects with persistent corneal epithelial defects (NEXPEDE-1).
This study is authorised, which means it has been approved to move forward, and it is listed as a Phase 2 interventional trial.
Who is being studied
The trial is focused on people with persistent corneal epithelial defects, a condition where the surface of the cornea does not heal normally.
In simple terms, the cornea is the clear front part of the eye, and the study is looking at whether treatment can help this surface close and stay healed.
The source data do not provide more detailed inclusion or exclusion rules, so the main target group we can confirm is subjects with this eye condition.
What the study is measuring
The main outcome is the proportion of subjects who achieve corneal re-epithelialization that is maintained for at least 28 days.
Corneal re-epithelialization means the cornea has formed a new surface layer again, which is a sign of healing.
Researchers assess this using corneal fluorescein staining images reviewed by a central reading center (CRC), which is a group that checks images in a standard way.
The brief summary also says the study is evaluating both safety and efficacy, meaning whether the treatment can be used safely and whether it helps the condition improve.
Study treatment and comparison
The trial compares NEXAGON with a vehicle, which is a sterile gel without the active ingredient Lufepirsen.
The vehicle contains poloxamer 407, sodium phosphate dibasic heptahydrate, potassium dihydrogen phosphate, and sterile water for injection, but it does not contain the API, meaning the active pharmaceutical ingredient.
NEXAGON is given topically, which means it is applied directly to the eye surface.
The source lists two NEXAGON dosing entries, 0.02 mg/Kg topical and 0.18 mg topical, but it does not explain here how these are assigned across groups.
Study design and phase
This is an interventional study, so researchers actively give a treatment and compare results between groups.
It is a Phase 2 trial, which usually means the study is early enough to still focus on safety while also testing whether the treatment shows signs of benefit.
The planned enrollment is 120 subjects, giving the study a moderate size for this stage of research.
Why this trial matters
Persistent corneal epithelial defects can be difficult to heal, so a trial like this is important because it looks at whether the corneal surface can close and remain healed for a meaningful period.
For patients, the key point is that the study is not just checking short-term improvement; it is measuring whether healing lasts for 28 days or more.
At this time, the information provided describes one authorised Phase 2 study of Lufepirsen in this eye condition, so the clinical trial picture is focused and specific.